Drug Profile
PF 6291874
Alternative Names: PF-06291874; PF-6291874Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 09 Jun 2017 Pharmacodynamics and adverse events data from a phase II trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
- 01 Nov 2016 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO) (Pfizer pipeline, February 2017)
- 01 Nov 2016 Discontinued - Phase-II for Type-2 diabetes mellitus in USA, Canada (PO) (Pfizer pipeline, February 2017)